HOWL - Werewolf Therapeutics - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079
Cancer, Immunotherapy, Interleukin, Interferon, IL-21, IL-18
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Web URL: https://werewolftx.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
HOWL Stock Overview
| Market Cap in USD | 93m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2021-04-30 |
HOWL Stock Ratings
| Growth 5y | -49.0 |
| Fundamental | -61.4 |
| Dividend | 0.00 |
| Rel. Performance vs Sector | -6.64 |
| Analysts | 4.67/5 |
| Fair Price Momentum | 2.21 USD |
| Fair Price DCF | - |
HOWL Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
HOWL Growth Ratios
| Growth 12m | 0.00% |
| Growth Correlation 12m | 28% |
| Growth Correlation 3m | -70% |
| CAGR 5y | -42.10% |
| CAGR/Mean DD 5y | -0.63 |
| Sharpe Ratio 12m | -0.05 |
| Alpha vs SP500 12m | -24.48 |
| Beta vs SP500 5y weekly | 1.24 |
| ValueRay RSI | 44.70 |
| Volatility GJR Garch 1y | 111.63% |
| Price / SMA 50 | -18.02% |
| Price / SMA 200 | -36.21% |
| Current Volume | 166.1k |
| Average Volume 20d | 484.2k |
External Links for HOWL Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of HOWL stocks?
As of July 27, 2024, the stock is trading at USD 2.73 with a total of 166,103 shares traded.
Over the past week, the price has changed by +0.37%, over one month by +16.67%, over three months by -59.56% and over the past year by +1.49%.
As of July 27, 2024, the stock is trading at USD 2.73 with a total of 166,103 shares traded.
Over the past week, the price has changed by +0.37%, over one month by +16.67%, over three months by -59.56% and over the past year by +1.49%.
What are the forecast for HOWL stock price target?
According to ValueRays Forecast Model, HOWL Werewolf Therapeutics will be worth about 2.5 in July 2025. The stock is currently trading at 2.73. This means that the stock has a potential downside of -9.52%.
According to ValueRays Forecast Model, HOWL Werewolf Therapeutics will be worth about 2.5 in July 2025. The stock is currently trading at 2.73. This means that the stock has a potential downside of -9.52%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 12.5 | 358 |
| Analysts Target Price | 12.2 | 347 |
| ValueRay Target Price | 2.5 | -9.52 |